Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2737298 | 0.81 | AAK1 (0.34) | HRH4RPS6KA3AAK1TLR9TLR8 | |
| SCHEMBL21023372 | 0.80 | TSHR (0.37) | HRH4AAK1 | |
| SCHEMBL15248196 | 0.80 | RPS6KA3 (0.39) | HRH4RPS6KA3ALOX5APFEN1EIF4A3 | |
| SCHEMBL26036544 | 0.78 | RPS6KA3 (0.34) | HRH4RPS6KA3ALOX5APFEN1EIF4A3 | |
| SCHEMBL10222482 | 0.77 | CYP2A6 (0.35) | CYP2A6TLR9TLR8TLR7 | |
| SCHEMBL17877178 | 0.77 | RPS6KA3 (0.33) | HRH4RPS6KA3ALOX5APFEN1ANPEP | |
| SCHEMBL25706405 | 0.77 | RPS6KA3 (0.33) | HRH4RPS6KA3ALOX5APFEN1 | |
| SCHEMBL18609308 | 0.77 | NOS2 (0.39) | HRH4RPS6KA3AAK1ALOX5APFEN1 | |
| SCHEMBL22870345 | 0.76 | CYP2A6 (0.34) | CYP2A6 | |
| SCHEMBL19766655 | 0.75 | TRPA1 (0.33) | RPS6KA3ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20220213107-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| EP-4006034-A1 | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11225486-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2022-01-18 | — | — | US | disclosed |
| EP-3697789-B1 | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2021032209-A1 | ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF | 四川海思科制药有限公司 | 2021-02-25 | — | — | WO | disclosed |
| US-20200385392-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-10738057-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-9708331-B2 | Metabotrophic glutamate receptor 5 modulators and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170121329-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-9550779-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9518057-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160251359-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2016-09-01 | — | — | US | disclosed |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185778-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-9260452-B2 | Metabotrophic glutamate receptor 5 modulators and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20140349993-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2014-11-27 | — | — | US | disclosed |
| US-20140179682-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | HRH4 4261/4885RPS6KA3 2247/4885AAK1 2183/4885 |
| US-20170121329-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | HRH4 2730/4885RPS6KA3 2498/4885AAK1 4102/4885 |
| US-20160185778-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | HRH4 2730/4885RPS6KA3 2498/4885AAK1 4102/4885 |
| US-20140349993-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HRH4 3580/4885RPS6KA3 1558/4885AAK1 2011/4885 |
| US-20160251359-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | GRM5, GRIK5, GRM2 | HRH4 560/4885RPS6KA3 1905/4885AAK1 1850/4885 |
| US-10738057-B2 | Tertiary alcohols as PI3K-γ inhibitors | PIK3R5, PIK3CG, PIK3CD | HRH4 4212/4885RPS6KA3 504/4885AAK1 1155/4885 |
| US-20220213107-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | HRH4 4342/4885RPS6KA3 440/4885AAK1 938/4885 |
| US-20140179682-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | GRM5, GRIK5, GRM2 | HRH4 560/4885RPS6KA3 1905/4885AAK1 1850/4885 |
| US-20200385392-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | HRH4 4342/4885RPS6KA3 440/4885AAK1 938/4885 |
| US-11225486-B2 | Tertiary alcohols as PI3K-γ inhibitors | PIK3R5, PIK3CG, PIK3CD | HRH4 4212/4885RPS6KA3 504/4885AAK1 1155/4885 |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | HRH4 2730/4885RPS6KA3 2498/4885AAK1 4102/4885 |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | HRH4 1219/4885RPS6KA3 3555/4885AAK1 721/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | HRH4 1219/4885RPS6KA3 3555/4885AAK1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.